Hepatotoxicity is the risk factor with gemtuzumab ozogamicin treatment in acute myelogenous leukaemia patients
Related Experiment Video
Updated: Dec 20, 2025

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
Published on: June 17, 2022
Sayed Aliul Hasan Abdi1, Shatrunajay Shukla2, Jasim Khan3
1Department of Medical Elementology & Toxicology, Jamia Hamdard (Hamdard University), New Delhi, India; Department of Pharmacology, Jamia Hamdard (Hamdard University), New Delhi, India; Department of Pharmacy, Al Baha University, Kingdom of Saudi Arabia.
No abstract available in PubMed .
More Related Videos
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
07:38Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
Related Concept Videos
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...